Skip to main content

NCBiotech News

  • Scioderm, a Durham-based biopharmaceutical company, has agreed with the U.S. Food and Drug Administration to submit a rolling New Drug Application (NDA) for Zorblisa, its topical therapy for the treatment of blisters and lesions in patients with epidermolysis bullosa, a rare genetic disease.
  • NCBiotech grant support helps Piedmont Triad nanoscientists pursue commercialization of potentially useful applications in reproducing the intricate ways insects' exteriors are constructed.
  • High Point clinical-stage pharmaceutical company vTv Therapeutics has filed a registration statement with the U.S. Securities and Exchange Commission to raise up to $173 million in an initial public offering of shares of its Class A common stock.
  • AgBiome of Research Triangle Park has formed a strategic partnership with Genective, a French company that develops biotech corn seed, to discover new ways to control insects in crops.
  • Bioscience briefs with names making news
  • A high-profile collaboration announced today by Durham biopharmaceutical company Spyryx Biosciences is the latest in a string of breathtaking announcements by three young Durham companies with promising treatments for deadly lung diseases.
  • T3D Therapeutics, a young Research Triangle Park company started with loan help from the North Carolina Biotechnology Center, has received approval from the Food and Drug Administration to test its lead drug candidate in patients with Alzheimer’s disease.
  • Bayer CropScience continued to dazzle observers at its North American and global Seeds headquarters today with a grand opening of a $33 million office renovation project while also breaking adjacent ground for a $34 million research greenhouse.
  • Timothy “Timm” Crowder, Ph.D., an entrepreneurial expert in design and development of inhaler technologies for lung therapies, has joined pharmaceutical startup Spyryx Biosciences as vice president of technical operations.
  • The president of Chapel Hill pharmaceutical start-up Eppin Pharmasays a $75,000 loan late last year from the North Carolina Biotechnology Center was an “absolutely critical” lead-in to a $225,000 NIH grant announced today.
  • When it comes to the $24 billion outsourced drug development industry, North Carolina is the undisputed – and still undefeated – heavyweight champion of the world. It's home to 128 contract research organizations employing over 21,000 people within the state and tens of thousands of others around the world.
  • North Carolina has substantial university and company assets devoted to health informatics, a quickly evolving SuperScieNCe field that uses databases, electronic medical records, bioinformatics and other tools to support clinical decisions that improve health care efficiency, delivery and outcomes.
  • Delivering precise treatments customized for each person’s unique genetic makeup is the powerful promise of personalized medicine, and North Carolina is already a leader in this new era of genomics-based health care.
  • Companies and university researchers across North Carolina are harnessing compounds, microorganisms and unique materials to bring advanced wound healing, surgical devices and regenerative medicine to civilian and military markets.
  • North Carolina is one of the world’s leading centers for the manufacture of biologics, pharmaceuticals, vaccines, diagnostics, medical devices and related products.
  • A study of the state’s life science landscape by the Battelle lists crop genetic engineering as one of six emerging life science technology sectors likely to flourish into the future. The  Technology Partnership Practice
  • North Carolina’s life science sector grew four times faster than that of the rest of the nation over the last decade. Even so, a study of the state’s industry says the best is yet to come, as the state builds on its “SuperSciNCe” – its prodigious research and innovation strengths in such growing markets as medicine, agriculture, biomanufacturing and health informatics.
  • Funding and other support from the North Carolina Biotechnology Center helped lay important groundwork for a possible $1.2 billion influx from Vertex Pharmaceuticals to Durham cystic fibrosis drug developer Parion Sciences.
  • Durham-based Viamet Pharmaceuticals has won a $1.95 million grant from the Department of Defense to develop a topical antifungal agent for preventing and treating mold infections in soldiers with battlefield wounds.
  • Morrisville medical imaging company Bioptigen, a 2004 Duke University spinout which makes specialized high-resolution imaging devices for non-invasive diagnoses of eye diseases and other medical applications, has reached agreement to be purchased by German powerhouse Leica Microsystems.


Subscribe to News & Events